美国食品和药物管理局的决定导致癌症药物开发商Kazia Therapeutics和Verastem Oncology的股票波动. FDA decisions caused stock fluctuations for cancer drug developers Kazia Therapeutics and Verastem Oncology.

在 FDA 表示总生存数据不适合加速批准其胶质母细胞瘤治疗药物 paxalisib，但可以支持标准批准后，Kazia Therapeutics 的股票下跌。 Kazia Therapeutics' stock dropped after the FDA said overall survival data isn't suitable for accelerated approval of its glioblastoma treatment, paxalisib, but could support standard approval. 与此同时,Verastem瘤学公司的股票上了26.4%,因为FDA接受了其针对avutometinib的NDA,该药用于治疗具有KRAS突变的复发性卵巢癌. Meanwhile, Verastem Oncology's stock rose 26.4% as the FDA accepted its NDA for avutometinib, aimed at treating recurrent ovarian cancer with a KRAS mutation. 该申请的执行日期为2025年6月30日。 The application has a PDUFA action date of June 30, 2025.